- complete GALAXY non-small cell lung cancer phase 2b enrollment in next couple of months (4q-2012)
- final PFS data 1h-2013
- more phase 3 detail at ESMO - explain why we made the "go" decision
- phase 3 to start by ye-2012, final data in 2014..."there may well be" interim data in 2013
- we are in the middle of interim analysis [to be presented at ESMO]
- confirmed increased bleeding in squamous pts, ganetespib yields "detriment in surivival" in this population
- we are seeing bigger effect on OS vs PFS - rare among cancer drugs
- ganetespib/HSP90 inhibition is a "third way to inhibit angiogenesis" by inhibiting transcription, vs blocking ligand or receptor
- Note: the company did not show LDH, kRAS subgroup data in this slide deck - a red flag for the early signals observed in this groups not holding up and that the phase 3 trial might be in a broader population after all - as I commented about immediately after the webcast at another website
Cleaning out my notes, so excuse the tardiness, but posting for context. Get more background of Synta Pharma $SNTA and ganetespib, or learn about the HSP90 inhibitor class generally.
0 Comments
Quick notes from the Isis Pharma $ISIS conference call after tepid endorsement of KYNAMRO (mipomersen) by the FDA metabolic and endocrine products advisory committee. You can find more of my commentary on this event (as well as competitor Aegerion Pharma $AEGR and their drug lomitapide) on the Chimera Research Group blog.
|
Categories
All
Archives
January 2020
|